Effects of Metformin and Pioglitazone on Serum Pentosidine Levels in Type 2 Diabetes Mellitus

Abstract

Objective: Accumulation of advanced glycation end products (AGEs) is associated with age- and diabetes-related disease. The aim of the present study is to investigate the effects of metformin or pioglitazone on serum pentosidine levels, a well-defined AGE, in type 2 diabetes.

Research Design and Methods: 66 Japanese patients were enrolled in this 6 months open-label study. In the metformin (n=22), the pioglitazone (n=22), and the control (optimal diet therapy, sulfonylurea and/or insulin) groups (n=22), serum levels of HbA_1c and pentosidine were measured at baseline and 6 months after each treatment.

Results: HbA_1c and pentosidine levels were not different at baseline among 3 groups, and HbA_1c was significantly decreased at 6 months in each group. In the metformin and the pioglitazone groups, serum pentosidine levels were significantly decreased at 6 months after treatments (p=0.039 and p=0.031, respectively). Percent changes in pentosidine levels in the metformin and the pioglitazone groups were significantly lower than that in the control group (p=0.012 and p=0.019, respectively).

Conclusion: 6 months treatments with metformin or pioglitazone in clinical doses decreased serum pentosidine levels which resulted in greater %change of serum pentosidine levels than the control group, suggesting that these agents may prevent the diabetic complications associated with AGEs accumulation.

Key words

pentosidine - metformin - pioglitazone - type 2 diabetes mellitus - advanced glycation end product

References

• 1 Aso Y, Inukai T, Tayama K. et al . Serum concentrations of advanced glycation end products are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes.  Acta Diabetol. 2000;  37 87-92
• 2 Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes.  Diabetes Metab. 2003;  29 6S95-6S103
• 3 Betteridge DJ. What is oxidative stress?.  Metabolism. 2002;  49 3-8
• 4 Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.  N Engl J Med. 1988;  318 1315-1321
• 5 Brownlee M. Advanced protein glycosylation in diabetes and aging.  Annu Rev Med. 1995;  46 223-234
• 6 Brownlee M. Biochemistry and molecular cell biology of diabetic complications.  Nature. 2001;  414 813-820
• 7 Daimon M, Ono Y, Saito T. et al . Increased serum levels of pentosidine, but not carboxymethyl lysine, in type 2 diabetes without obvious diabetic nephropathy.  Diabetes Care. 1999;  22 877-878
• 8 Goldin A, Beckman JA, Schmidt AM. et al . Advanced glycation end products sparking the development of diabetic vascular injury.  Circulation. 2006;  114 597-605
• 9 Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors.  J Biol Chem. 1991;  266 11649-11653
• 10 Hannon R, Blumsohn A, Naylor K. et al . Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.  J Bone Miner Res. 1998;  13 1124-1133
• 11 Iida KT, Kawakami Y, Suzuki M. et al . Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.  Am J Physiol Endocrinol Metab. 2003;  284 E1125-E1130
• 12 Kilhovd BK, Berg TJ, Birkeland KI. et al . Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.  Diabetes Care. 1999;  22 1543-1548
• 13 Lapolla A, Reitano R, Baccarin L. et al . Pentosidine plasma levels and relation with metabolic control in diabetic patients.  Horm Metab Res. 2005;  37 252-256
• 14 Meil M, Perier C, Ferron C. et al . Serum pentosidine as an indicator of Alzheimer's disease.  J Alzheimers Dis. 2002;  4 93-96
• 15 Miyata T, Ishikawa S, Asahi K. et al . 2-Isopropylidenehydrozono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage.  FEBS Lett. 1999;  445 202-206
• 16 Monnier VM, Sell DR, Nagaraj RH. et al . Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia.  Diabetes. 1992;  41 36-41
• 17 Monnier VM, Bautista O, Kenny D. et al . the DCCT Skin Collagen Ancillary Study Group. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus HbA_1c as markers of diabetic complications.  Diabetes. 1999;  48 870-880
• 18 Odetti P, Fogarty J, Sell DR. et al . Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects.  Diabetes. 1992;  41 153-159
• 19 Phillips SA, Thornalley PJ. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal.  Eur J Biochem. 1993;  212 101-105
• 20 Rahbar S, Natarajan R, Yerneni K. et al . Evidence that pioglitazone, metformin and pentoxifylline are inhibitiors of glycation.  Clin Chim Acta. 2000;  301 65-77
• 21 Sanaka T, Funaki T, Tanaka T. et al . Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure.  Nephron. 2002;  91 64-73
• 22 Schwartz AV, Garnero P, Hillier TA. et al . Health, Aging, and Body Composition Study. Pentosidine and increased fracture risk in older adults with type 2 diabetes.  J Clin Endocrinol Metab. 2009;  94 2380-2386
• 23 Singh R, Barden A, Mori T. et al . Advanced glycation end-products a review.  Diabetologia. 2001;  44 129-146
• 24 Sugiyama S, Miyata T, Ueda Y. et al . Plasma levels of pentosidine in diabetic patients: an advanced glycation end product.  J Am Soc Nephrol. 1998;  9 1681-1688
• 25 Tessier D, Maheux P, Khalil A. et al . Effect of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes.  Metabolism. 1999;  48 897-903
• 26 Torrens JI, Skurnick J, Davidow AL. et al . Study of Women's Health Across the Nation (SWAN) Ethnic differences in insulin sensitivity and beta-cell function in premenopaulsa or early perimenopausal women without diabetes: the Study of Women's Health Across the Nation (SWAN).  Diabetes Care. 2004;  27 354-361
• 27 van Deemter M, Ponsioen TL, Bank RA. et al . Pentosidine accumulates in the aging vitreous body: a gender effect.  Exp Eye Res. 2009;  88 1043-1050
• 28 Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications.  Diabetes Metab Res Rev. 2001;  17 436-443
• 29 Weiss MF, Rodby RA, Justice AC. et al . Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Collaborative Study Group.  Kidney Int. 1998;  54 193-202
• 30 Yamamoto M, Yamaguchi T, Yamauchi M. et al . Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes.  J Clin Endocrinol Metab. 2008;  93 1013-1019
• 31 Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes.  Metabolism. 2005;  54 345-350

Correspondence